- Home
- RIO vs ABBV Comparison
RIO vs ABBV Comparison
Compare RIO & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIO | ABBV |
|---|---|---|
| Founded | 1873 | 2012 |
| Country | United Kingdom | United States |
| Employees | 61230 | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.8B | 358.5B |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | RIO | ABBV |
|---|---|---|
| Price | $93.76 | $245.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 18 |
| Target Price | $88.50 | ★ $253.71 |
| AVG Volume (30 Days) | 2.6M | ★ 4.1M |
| Earning Date | 02-19-2026 | 04-29-2026 |
| Dividend Yield | ★ 4.14% | 3.39% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.39 |
| Revenue | N/A | ★ $61,160,000,000.00 |
| Revenue This Year | $10.99 | $11.87 |
| Revenue Next Year | $2.64 | $8.12 |
| P/E Ratio | ★ $15.76 | $625.28 |
| Revenue Growth | N/A | ★ 8.57 |
| 52 Week Low | $57.66 | $181.75 |
| 52 Week High | $112.58 | $244.81 |
Technical Indicators
Market Signals| Indicator | RIO | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 35.11 | 72.46 |
| Support Level | $81.00 | $213.65 |
| Resistance Level | $100.90 | N/A |
| Average True Range (ATR) | 1.84 | 5.73 |
| MACD | -1.26 | 1.95 |
| Stochastic Oscillator | 3.25 | 89.64 |
Price Performance
Historical ComparisonAbout RIO Rio Tinto Plc
Rio Tinto is a global diversified miner. Iron ore is its major commodity, with lesser contributions from copper and aluminum. Lithium, diamonds, gold, and industrial minerals are more minor contributors. The 1995 merger of RTZ and CRA, via a dual-listed structure, created the present-day company. The two operate as a single business entity, with shareholders in each company having equivalent economic and voting rights. Major assets included the Pilbara iron ore operations, a 30% stake in the Escondida copper mine, 66%-ownership of the Oyu Tolgoi copper mine in Mongolia, the Weipa and Gove bauxite mines in Australia, and six hydro-powered aluminum smelters in Canada.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.